CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于实体瘤免疫治疗的 NKG2D CAR-T 细胞：进展、挑战与未来方向
英文原题：NKG2D CAR-T cells for solid tumor immunotherapy: advances, challenges, and future directions.
查看英文原题
NKG2D CAR-T cells for solid tumor immunotherapy: advances, challenges, and future directions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法在血液系统恶性肿瘤中取得了显著成功，但其在实体瘤中的疗效仍然有限，主要原因是免疫抑制性肿瘤微环境（TME）阻碍了CAR-T 细胞的迁移和功能。NKG2D CAR-T 细胞靶向肿瘤细胞广泛表达的应激诱导NKG2D配体（NKG2DLs），在克服实体瘤TME的免疫抑制屏障方面显示出有前景的潜力。本综述重点介绍了NKG2D CAR-T 细胞策略用于实体瘤的最新进展，包括CAR结构创新、信号通路工程、联合免疫治疗以及装甲CAR构建体的开发。我们进一步讨论了这些方法的治疗潜力、当前挑战和未来方向，以期为设计更有效、更持久的实体瘤CAR-T 细胞疗法提供参考。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in hematologic malignancies, but its efficacy in solid tumors remains limited, primarily due to the immunosuppressive tumor microenvironment (TME) that hinders CAR-T cell trafficking and function.
NKG2D CAR-T cells, which target stress-induced NKG2D ligands (NKG2DLs) broadly expressed on tumor cells, have shown promising potential in overcoming the immunosuppressive barriers of the solid TME. This review highlights recent advances in NKG2D CAR-T cell strategies for solid tumors, including innovations in CAR architecture, signaling pathway engineering, combination immunotherapy, and the development of armored CAR constructs.
We further discuss the therapeutic potential, current challenges, and future directions of these approaches to inform the design of more effective and durable CAR-T cell therapies for solid tumors.
论文信息
- 作者
- Liu C、Wang Z、Zhang W、Cheng G、Cheng S、Qin L、Ye H、Ren W
- 单位
- Cuiying Biomedical Research Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2026
- 原文标识
- PubMed 41756289 · DOI 10.3389/fimmu.2026.1763843
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →